Priyanka Uprety1, Ellen G Chadwick2, Kaitlin Rainwater-Lovett3, Carrie Ziemniak3, Katherine Luzuriaga4, Edmund V Capparelli5, Gayane Yenokyan6, Deborah Persaud3. 1. W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Department of Pediatrics, Northwestern University School of Medicine, Chicago, Illinois. 3. Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland. 4. Department of Pediatrics, University of Massachusetts Medical School, Worcester. 5. Department of Pediatrics, University of California, San Diego. 6. Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Abstract
BACKGROUND: The decay of human immunodeficiency virus type 1 (HIV-1)-infected cells during early combination antiretroviral therapy (cART) in infected infants is not defined. METHODS: HIV-1 DNA, including 2-long terminal repeat (2-LTR) circles, and multiply spliced (ms-) and unspliced (us-) HIV-1 RNA concentrations were measured at 0, 24, 48, and 96 weeks of cART in infants from the IMPAACT P1030 trial receiving lopinavir-ritonavir-based cART. The ratio of HIV-1 DNA concentrations to replication-competent genomes was also estimated. Linear mixed effects models with random intercept and linear splines were used to estimate patient-specific decay kinetics of HIV-1 DNA. RESULTS: The median HIV-1 DNA concentration before cART at a median age of 2 months was 3.2 log10 copies per million PBMC. With cART, the average estimated patient-specific change in HIV-1 DNA concentrations was -0.040 log10/week (95% confidence interval [CI], -.05, -.03) between 0 and 24 weeks and -0.017 log10/week between 24 and 48 weeks (95% CI, -.024, -.01). 2-LTR circles decreased with cART but remained detectable through 96 weeks. Pre-cART HIV-1 DNA concentration was correlated with time to undetectable plasma viral load and post-cART HIV-1 DNA at 96 weeks; although HIV-1 DNA concentrations exceeded replication-competent HIV-1 genomes by 148-fold. Almost all infants had ms- and usRNA detected pre-cART, with 75% having usRNA through 96 weeks of cART. CONCLUSIONS: By 2 months of age, a large pool of HIV-1-infected cells is established in perinatal infection, which influences time to undetectable viral load and reservoir size. This has implications for informing novel approaches aimed at early restriction of HIV-1 reservoirs to enable virologic remission and cure.
BACKGROUND: The decay of human immunodeficiency virus type 1 (HIV-1)-infected cells during early combination antiretroviral therapy (cART) in infected infants is not defined. METHODS:HIV-1 DNA, including 2-long terminal repeat (2-LTR) circles, and multiply spliced (ms-) and unspliced (us-) HIV-1 RNA concentrations were measured at 0, 24, 48, and 96 weeks of cART in infants from the IMPAACT P1030 trial receiving lopinavir-ritonavir-based cART. The ratio of HIV-1 DNA concentrations to replication-competent genomes was also estimated. Linear mixed effects models with random intercept and linear splines were used to estimate patient-specific decay kinetics of HIV-1 DNA. RESULTS: The median HIV-1 DNA concentration before cART at a median age of 2 months was 3.2 log10 copies per million PBMC. With cART, the average estimated patient-specific change in HIV-1 DNA concentrations was -0.040 log10/week (95% confidence interval [CI], -.05, -.03) between 0 and 24 weeks and -0.017 log10/week between 24 and 48 weeks (95% CI, -.024, -.01). 2-LTR circles decreased with cART but remained detectable through 96 weeks. Pre-cART HIV-1 DNA concentration was correlated with time to undetectable plasma viral load and post-cART HIV-1 DNA at 96 weeks; although HIV-1 DNA concentrations exceeded replication-competent HIV-1 genomes by 148-fold. Almost all infants had ms- and usRNA detected pre-cART, with 75% having usRNA through 96 weeks of cART. CONCLUSIONS: By 2 months of age, a large pool of HIV-1-infected cells is established in perinatal infection, which influences time to undetectable viral load and reservoir size. This has implications for informing novel approaches aimed at early restriction of HIV-1 reservoirs to enable virologic remission and cure.
Authors: A G Fisher; M B Feinberg; S F Josephs; M E Harper; L M Marselle; G Reyes; M A Gonda; A Aldovini; C Debouk; R C Gallo Journal: Nature Date: 1986 Mar 27-Apr 2 Impact factor: 49.962
Authors: Alison L Hill; Daniel I S Rosenbloom; Feng Fu; Martin A Nowak; Robert F Siliciano Journal: Proc Natl Acad Sci U S A Date: 2014-08-05 Impact factor: 11.205
Authors: Deborah Persaud; Hannah Gay; Carrie Ziemniak; Ya Hui Chen; Michael Piatak; Tae-Wook Chun; Matthew Strain; Douglas Richman; Katherine Luzuriaga Journal: N Engl J Med Date: 2013-10-23 Impact factor: 91.245
Authors: Guillaume J Besson; Christina M Lalama; Ronald J Bosch; Rajesh T Gandhi; Margaret A Bedison; Evgenia Aga; Sharon A Riddler; Deborah K McMahon; Feiyu Hong; John W Mellors Journal: Clin Infect Dis Date: 2014-07-29 Impact factor: 9.079
Authors: Ya-Chi Ho; Liang Shan; Nina N Hosmane; Jeffrey Wang; Sarah B Laskey; Daniel I S Rosenbloom; Jun Lai; Joel N Blankson; Janet D Siliciano; Robert F Siliciano Journal: Cell Date: 2013-10-24 Impact factor: 41.582
Authors: Matthew C Strain; Steven M Lada; Tiffany Luong; Steffney E Rought; Sara Gianella; Valeri H Terry; Celsa A Spina; Christopher H Woelk; Douglas D Richman Journal: PLoS One Date: 2013-04-03 Impact factor: 3.240
Authors: Catherine G Sutcliffe; Janneke H van Dijk; Francis Hamangaba; Felix Mayani; William J Moss Journal: PLoS One Date: 2014-01-24 Impact factor: 3.240
Authors: C Korin Bullen; Gregory M Laird; Christine M Durand; Janet D Siliciano; Robert F Siliciano Journal: Nat Med Date: 2014-03-23 Impact factor: 53.440
Authors: Steven G Deeks; Sharon R Lewin; Anna Laura Ross; Jintanat Ananworanich; Monsef Benkirane; Paula Cannon; Nicolas Chomont; Daniel Douek; Jeffrey D Lifson; Ying-Ru Lo; Daniel Kuritzkes; David Margolis; John Mellors; Deborah Persaud; Joseph D Tucker; Françoise Barre-Sinoussi; Galit Alter; Judith Auerbach; Brigitte Autran; Dan H Barouch; Georg Behrens; Marina Cavazzana; Zhiwei Chen; Éric A Cohen; Giulio Maria Corbelli; Serge Eholié; Nir Eyal; Sarah Fidler; Laurindo Garcia; Cynthia Grossman; Gail Henderson; Timothy J Henrich; Richard Jefferys; Hans-Peter Kiem; Joseph McCune; Keymanthri Moodley; Peter A Newman; Monique Nijhuis; Moses Supercharger Nsubuga; Melanie Ott; Sarah Palmer; Douglas Richman; Asier Saez-Cirion; Matthew Sharp; Janet Siliciano; Guido Silvestri; Jerome Singh; Bruno Spire; Jeffrey Taylor; Martin Tolstrup; Susana Valente; Jan van Lunzen; Rochelle Walensky; Ira Wilson; Jerome Zack Journal: Nat Med Date: 2016-07-11 Impact factor: 53.440
Authors: Kirsten A Veldsman; Jean Maritz; Shahieda Isaacs; Mary G Katusiime; Anita Janse van Rensburg; Barbara Laughton; John W Mellors; Mark F Cotton; Gert U van Zyl Journal: AIDS Date: 2018-03-13 Impact factor: 4.177